Advanced Neuromodulation Systems, Inc. | Abbott Laboratories | HHS civil monetary penalties | 2007 | HHSOIG | $2,950,000 |
Abbott Laboratories | Abbott Laboratories | off-label or unapproved promotion of medical products | 2018 | USAO | $25,000,000 |
Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Actavis Kadian, LLC | AbbVie | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $116,703 |
Abbott Laboratories | AbbVie | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $14,750,000 |
Allergan Finance LLC | AbbVie | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
Allergan Ltd. et al. | AbbVie | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
Allergan Ltd. | AbbVie | off-label or unapproved promotion of medical products | 2022 | RI-AG | $7,500,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | WV-AG | $78,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $2,370,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $27,000,000 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,800,000 |
Allergan PLC | AbbVie | off-label or unapproved promotion of medical products | 2023 | KY-AG | $48,666,145 |
Allergan | AbbVie | off-label or unapproved promotion of medical products | 2024 | MD-AG | $38,166,450 |
Alnylam Pharmaceuticals, Inc. | Alnylam Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2023 | CMS | $31,959 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $612,000,000 |
Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | $71,000,000 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $5,909 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2015 | CMS | $9,440 |
Amneal Pharmaceutical, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $10,788 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2016 | CMS | $12,367 |
Amneal Pharmaceuticals, LLC | Amneal Pharmaceuticals | Medicare Coverage Gap Discount Program violation | 2019 | CMS | $12,968 |
AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
AstraZeneca | AstraZeneca | off-label or unapproved promotion of medical products | 2013 | KY-AG | $5,500,000 |
AstraZeneca Pharmaceuticals | AstraZeneca | off-label or unapproved promotion of medical products | 2011 | MULTI-AG | $68,500,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $9,800,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Medicis Pharmaceutical Corporation | Bausch Health | off-label or unapproved promotion of medical products | 2007 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,000,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Boehringer Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | $13,500,000 |
Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $95,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
Bristol-Myers Squibb | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2016 | MULTI-AG | $19,500,000 |
Celgene Corp. | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2017 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $20,700,000 |
Cypress Pharmaceutical Inc. | Currax Pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $2,800,000 |
Eisai Inc. | Eisai | off-label or unapproved promotion of medical products | 2010 | FDA | $11,000,000 |
Eisai Inc. | Eisai | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,658,249 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
Eli Lilly | Eli Lilly | off-label or unapproved promotion of medical products | 2010 | AR-AG | $18,500,000 |
Eli Lilly | Eli Lilly | off-label or unapproved promotion of medical products | 2010 | MS-AG | $18,500,000 |
Eli Lilly | Eli Lilly | off-label or unapproved promotion of medical products | 2010 | LA-AG | $20,000,000 |
Eli Lilly and Co. | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | CT-AG | $25,100,000 |
Eli Lilly and Co. | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | ID-AG | $13,000,000 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | $62,000,000 |
Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $22,500,000 |
Endo Pharmaceuticals | Endo International | Controlled Substances Act violation | 2020 | OK-AG | $8,750,000 |
Endo Health Solutions | Endo International | off-label or unapproved promotion of medical products | 2021 | NY-AG | $50,000,000 |
Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Endo Health Solutions and Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | FL-AG | $65,000,000 |
Endo Pharmaceuticals | Endo International | off-label or unapproved promotion of medical products | 2022 | CA-SFCA | $10,000,000 |
Endo International plc | Endo International | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2010 | KY-AG | $3,700,000 |
GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2009 | KY-AG | $661,860 |
GlaxoSmithKline, LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2013 | MD-AG | $15,000,000 |
Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Scios Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Johnson & Johnson | Johnson & Johnson | Controlled Substances Act violation | 2008 | USAO | $511,000 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $24,681,516 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Janssen Pharmaceuticals/Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Mallinckrodt LLC | Mallinckrodt | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Inspire Pharmaceuticals Inc. | Merck | off-label or unapproved promotion of medical products | 2015 | USAO | $5,900,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Inspire Pharmaceuticals | Merck | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $29,000,000 |